NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $177.29 -1.21 (-0.68%) As of 03:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Quest Diagnostics Stock (NYSE:DGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Quest Diagnostics alerts:Sign Up Key Stats Today's Range$174.80▼$179.0850-Day Range$160.03▼$178.9252-Week Range$135.27▼$179.56Volume1.09 million shsAverage Volume962,635 shsMarket Capitalization$19.79 billionP/E Ratio23.05Dividend Yield1.80%Price Target$185.07Consensus RatingModerate Buy Company OverviewQuest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Read More… Quest Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreDGX MarketRank™: Quest Diagnostics scored higher than 91% of companies evaluated by MarketBeat, and ranked 15th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingQuest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageQuest Diagnostics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quest Diagnostics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth8.14% Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 8.14% in the coming year, from $9.70 to $10.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 23.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 23.05, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.39.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.16. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.15% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently increased by 22.38%, indicating that investor sentiment is decreasing significantly. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.84%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 40.46%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 30.51% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. Sustainability and ESG4.7 / 5Environmental Score-0.62 Percentage of Shares Shorted3.15% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently increased by 22.38%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.72 News SentimentQuest Diagnostics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 37 news articles for Quest Diagnostics this week, compared to 15 articles on an average week.Search InterestOnly 7 people have searched for DGX on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows8 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,460,221.00 in company stock.Percentage Held by InsidersOnly 8.16% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address DGX Stock News HeadlinesQuest Diagnostics Incorporated (NYSE:DGX) SVP Karthik Kuppusamy Sells 2,555 SharesApril 5, 2025 | insidertrades.comPiper Sandler Increases Quest Diagnostics (NYSE:DGX) Price Target to $200.00April 30 at 3:35 AM | americanbankingnews.comTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?April 30, 2025 | Porter & Company (Ad)Quest Diagnostics (NYSE:DGX) Reaches New 1-Year High Following Analyst UpgradeApril 30 at 2:33 AM | americanbankingnews.comQ3 EPS Estimate for Quest Diagnostics Raised by AnalystApril 26, 2025 | americanbankingnews.comLeerink Partnrs Issues Negative Outlook for DGX EarningsApril 26, 2025 | americanbankingnews.comDecoding Quest Diagnostics Inc (DGX): A Strategic SWOT InsightApril 26, 2025 | gurufocus.comLeerink Partnrs Has Pessimistic Outlook of DGX Q2 EarningsApril 25, 2025 | americanbankingnews.comSee More Headlines DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $150.86 at the beginning of 2025. Since then, DGX stock has increased by 17.5% and is now trading at $177.29. View the best growth stocks for 2025 here. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) announced its earnings results on Tuesday, April, 22nd. The medical research company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.06. The medical research company had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.63 billion. Quest Diagnostics had a trailing twelve-month return on equity of 15.07% and a net margin of 8.80%. Read the conference call transcript. Does Quest Diagnostics have any subsidiaries? Quest Diagnostics subsidiaries include these companies: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and others. When did Quest Diagnostics IPO? Quest Diagnostics (DGX) raised $12 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 2,300,000 shares at $4.00-$6.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO. Who are Quest Diagnostics' major shareholders? Top institutional investors of Quest Diagnostics include Bank of New York Mellon Corp (0.78%), DekaBank Deutsche Girozentrale (0.69%), Principal Financial Group Inc. (0.51%) and GAMMA Investing LLC (0.40%). Insiders that own company stock include Stephen H Rusckowski, J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Timothy M Ring, Vicky B Gregg, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Record date for 4/21 Dividend4/07/2025Ex-Dividend for 4/21 Dividend4/07/2025Dividend Payable4/21/2025Last Earnings4/22/2025Today4/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryHealth Care Services Current SymbolNYSE:DGX CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees49,000Year Founded1967Price Target and Rating Average Stock Price Target$185.07 High Stock Price Target$200.00 Low Stock Price Target$170.00 Potential Upside/Downside+4.5%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$7.91 Trailing P/E Ratio23.03 Forward P/E Ratio18.26 P/E Growth2.16Net Income$871 million Net Margins8.80% Pretax Margin11.90% Return on Equity15.07% Return on Assets6.72% Debt Debt-to-Equity Ratio0.82 Current Ratio1.10 Quick Ratio1.02 Sales & Book Value Annual Sales$10.16 billion Price / Sales1.95 Cash Flow$13.81 per share Price / Cash Flow12.82 Book Value$61.04 per share Price / Book2.90Miscellaneous Outstanding Shares111,635,000Free Float110,733,000Market Cap$19.77 billion OptionableOptionable Beta0.78 Social Links 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NYSE:DGX) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.